¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Paients with Cardiovascular Disease) 2022 (1ÀÏÂ÷) : 2022-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Paients with Cardiovascular Disease) 2022 (1ÀÏÂ÷) : 2022-06-17
±³À°ÀÏÀÚ : 2022-06-17
±³À°Àå¼Ò : ¼ÛµµÄÁº¥½Ã¾Æ ÇÁ¸®¹Ì¾îº¼·ë(2F)  
±³À°ÁÖÁ¦ : IPOP(Imaging and Physiology on Paients with Cardiovascular Disease) 2022 (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸  
´ã´çÀÚ : Á¤ÀºÇý
¿¬¶ôó : 02-582-8212  
À̸ÞÀÏ : grace@kscvi.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ÀÎõ±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 Hall A 13:00~13:10 Overview: Role of Imaging to Evaluate Plaque Characteristics  ÃÖ¼Ò¿¬(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 13:10~13:20 Multimodality Intravascular Imaging of High-risk Coronary Plaque  ±èÁø¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 13:20~13:30 Differential Immunophenotypings and OCT(Optical Coherence Tomography) Findings in ACS(Acute Coronary Syndrome) Patients  À̽·ü(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 13:30~13:40 Near Infrared Spectroscopy to Predict Coronary No-Reflow after PCI(Percutaneous Coronary Intervention)  Â÷Á¤ÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 13:40~13:50 Artificial Intelligence-assisted Coronary Plaque Characterization  °­¼öÁø(¿ï»êÀÇ´ë) 
Åä·Ð 06-17 Hall A 13:50~14:20 Discussion  () 
±³À°½Ã°£ 06-17 Hall B 13:00~13:10 Set-Up Your Pressure Wire Ready to Go FFR(Fractional Flow Reserve) Measurement  °íÁø½Å(°æ»óÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 13:10~13:20 Hyperemia Standardization  ÀåÈ£ÁØ(ºÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 06-17 Hall B 13:20~13:30 CFR(Coronary Flow Reserve), IMR(Index of Microvascular Resistance) Measurement  ¹Ú°æÀÏ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 13:30~13:40 iFR(Instantaneous Wave-free Ratio) Measurement Practice  ÀÓÈ«¼®(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 13:40~13:50 Coronary Physiology in Animal Experiment  ±èÇö±¹(Á¶¼±ÀÇ´ë) 
Åä·Ð 06-17 Hall B 13:50~14:20 Discussion  () 
±³À°½Ã°£ 06-17 Hall A 14:25~14:35 2 Stenting Strategy for Bifurcation Lesion  ÀÌ»ó¿±(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 14:35~14:45 1 Provisional Stenting for Bifurcation Lesion  À±Àç¿ë(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 14:45~14:55 Calcified Lesion  ÃÖÀÍÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 14:55~15:05 CTO(Chronic Total Occlusion)  ÀÌÁßÈñ(¿øÁÖ¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall A 15:05~15:15 AMI(Acute Myocardial Infarction)  ±è¿ëö(¿¬¼¼ÀÇ´ë) 
Åä·Ð 06-17 Hall A 15:15~15:35 Discussion  () 
±³À°½Ã°£ 06-17 Hall B 14:25~14:33 RIPCORD 2 Trial: Systemic FFR(Fractional Flow Reserve) at the Stage of Diagnostic CAG(Cardiac Angiography)  °­ÁöÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 14:33~14:41 What''s the Issues in RIPCORD 2 and How to Interpret the Results?  ¾ÈÁ¤¹Î(¿ï»êÀÇ´ë) 
Åä·Ð 06-17 Hall B 14:41~14:49 Discussion  () 
±³À°½Ã°£ 06-17 Hall B 14:49~14:57 FLOWER-AMI: Angio-guided PCI(Percutaneous Coronary Intervention) vs. FFR(Fractional Flow Reserve)-Guided PCI(Percutaneous Coronary Intervention) in STEMI(ST-Elevation Myocardial Infarction) Nonculprit  ±èÁöÇý(Áß¾Óº¸Èƺ´¿ø) 
±³À°½Ã°£ 06-17 Hall B 14:57~15:05 What''s the Issues in FLOWER-AMI and How to Interpret the Results?  ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë) 
Åä·Ð 06-17 Hall B 15:05~15:12 Discussion  () 
±³À°½Ã°£ 06-17 Hall B 15:12~15:20 FAME 3 - FFR(Fractional Flow Reserve)-guided Multivessel PCI(Percutaneous Coronary Intervention) vs. CABG(Coronary Artery Bypass Grafting)  Àå¿ìÁø(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 15:20~15:28 What''s the Issues in FAME 3 and How to Interpret the Results?  Á¶À±°æ(°è¸íÀÇ´ë) 
Åä·Ð 06-17 Hall B 15:28~15:35 Discussion  () 
±âŸ 06-17 Hall A 15:35~16:00 IPOP ÃÑȸ  () 
±³À°½Ã°£ 06-17 Hall A 16:00~17:20 Imaging Quiz Competition for Young Interventionists  ÀÓµµ¼±(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 16:00~16:12 Clinical Application of Coronary Physiology without Hyperemia  ÃßÀºÈ£(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 16:12~16:24 Clinical Application of Coronary Physiology for Post-PCI(Percutaneous Coronary Intervention) Optimization  È²µµ¿¬(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 16:24~16:36 Coronary Vasomotor Function Following DCB(Drug-coated Balloon) Only Angioplasty of De Novo Lesions  ±è¼±¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Hall B 16:36~16:48 Clinical Application of Coronary Physiology for Non-coronary Disease  ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë) 
Åä·Ð 06-17 Hall B 16:48~17:20 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Paients with Cardiovascular Disease) 2022 (1ÀÏÂ÷) : 2022-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÅëÁõÀÚÀ²½Å°æÇÐȸ ÇÏ°è Áý´ãȸ : 2022-06-17
´ÙÀ½±Û ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦2Â÷ ¿¬¼ö°­Á ¹× Á¤±âÇмú´ëȸ : 2022-06-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20835 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ 2024³â Á¦ 1ȸ ³»½Ã°æ Áý´ãȸ : 2024-06-21 0 4 2024-05-27
20834 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¾È°ú ±Ý¿äÁý´ãȸ : 2024-06-21 0 0 2024-05-27
20833 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 1ÀÏÂ÷ : 2024-06-21 0 0 2024-05-27
20832 ¼­¿ï Á¦8Â÷ µµºÀ±¸ÀÇ»çȸ Çмú¼¼¹Ì³ª(½ÉÇ÷°üÁúȯ ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á, ºÒ¸éÁõ, Ä¡¸Å¾à¹°Ä¡·á, Ç×Ç÷ÀüÁ¦) : 2024-06-21 0 0 2024-05-27
20831 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (2ÀÏÂ÷) : 2024-06-21 0 1 2024-05-27
20830 Á¦ÁÖ ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-21 0 0 2024-05-27
20829 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(1ÀÏÂ÷) : 2024-06-20 0 0 2024-05-27
20828 ºÎ»ê ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2024-06-20 0 3 2024-05-27
20827 ºÎ»ê ´ëÇѾȰúÇÐȸ ºÎ»êÁöȸ Á¦ 510ȸ ÇмúÁý´ãȸ : 2024-06-20 0 1 2024-05-27
20826 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (1ÀÏÂ÷) : 2024-06-20 0 0 2024-05-27
20825 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÅëÁõÇÐȸ ¼­¿ïÁöȸ Áý´ãȸ : 2024-06-20 0 0 2024-05-27
20824 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À°(¼­½Ä ÀÛ¼º ½ÇÁ¦) : 2024-06-20 0 0 2024-05-27
20823 °æ±â µ¿±¹´ëÇб³ Àϻ꺴¿ø : °ñ°üÀý¿°ÀÇ Áø´Ü ¹× Ä¡·á : 2024-06-19 0 1 2024-05-27
20822 °æ±â ´ëÇÑ°£ÇÐȸ Overlooked Liver Diseases : 2024-06-19 0 7 2024-05-27
20821 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦2ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-06-17 0 4 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷